Premium
Uterine myxoid leiomyosarcoma and CYVADIC‐etoposide therapy
Author(s) -
Fukunishi H.,
Yukimura N.,
Takeuchi S.,
Kitazawa S.
Publication year - 1994
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/0020-7292(94)90413-8
Subject(s) - medicine , etoposide , vincristine , dacarbazine , metastasis , leiomyosarcoma , epirubicin , chemotherapy , pathology , cyclophosphamide , cancer
Objectives: To conduct a pathological characterization of rare uterine myxoid leiomyosarcoma (MLS) and establish an effective chemotherapy for metastasis after hysterectomy. Methods: Histological and immunohistochemical methods were used to characterize the type of uterine MLS in a 39‐year‐old female. For multiple lung metastases found 3 months after operation, CYVADIC (400 mg cyclophosphamide, 1 mg vincristine, 50 mg epirubicin and 400 mg dacarbazine per body for one course) and oral etoposide (50 mg/body per day for 2 weeks) were applied. Results: The rapidly enlarging uterine tumors exhibited gelatinous cut surfaces, a high count of 30 mitotic cells per 10 hpf and mucinous stroma, indicating a rare high‐mitotic type of uterine MLS. The two‐course CYVADIC‐etoposide therapy was effective for disseminated pulmonary metastases. Conclusion: The present MLS was a rare high‐mitotic type. CYVADIC‐etoposide was an optional effective chemotherapy for lung metastasis in this case.